Clene (CLNN) vs XBiotech (XBIT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
XBiotech (XBIT) has outperformed Clene (CLNN) over the past year, losing 24.1% versus a loss of 62.0%. Over five years, XBIT leads with a -86.5% price change compared with -96.3% for CLNN. XBiotech is the larger company by market cap ($52.7 million vs $50.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLNN | XBIT |
|---|---|---|
| Share price | $3.52 | $1.73 |
| Market cap | $50.69M | $52.74M |
| 1-day change | +0.57% | +2.98% |
| YTD return | -40.03% | -27.62% |
| 1-year return | -62.03% | -24.12% |
| 5-year return | -96.28% | -86.48% |
| Forward P/E | — | 13.31 |
| EPS (TTM) | $-2.30 | $-1.43 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $200.00K | — |
| Revenue growth (YoY) | -41.52% | — |
| Net income (latest FY) | $-26.17M | $-45.54M |
| Gross margin | 78.50% | — |
| Operating margin | -11541.50% | — |
| Net margin | -13086.50% | — |
| 52-week high | $10.84 | $2.73 |
| 52-week low | $3.02 | $1.61 |
| Distance from 52-week high | -67.53% | -36.63% |
| Analyst consensus | none | — |
| Avg. price target upside | +814.77% | — |
| Average volume | 115.06K | 64.77K |
| Shares outstanding | 14.40M | 30.49M |
| Employees | 76 | 87 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- XBIT has outperformed CLNN by 37.9 percentage points over the past year.
About Clene
CLNN stock →Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company's lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees
About XBiotech
XBIT stock →XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 87 employees
CLNN vs XBIT FAQ
Which is bigger, Clene or XBiotech?
XBiotech (XBIT) is larger, with a market capitalization of $52.74M compared with $50.69M for Clene (CLNN).
Which stock has performed better over the past year, CLNN or XBIT?
XBIT returned -24.12% over the past 12 months, compared with -62.03% for CLNN (price return, excluding dividends). Past performance does not predict future results.
Are Clene and XBiotech in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.